January 11, 2018: Former New Hampshire Pharmacist Pleads Guilty for Tampering with Narcotics at Bedford Pharmacy
|
Food and Drug Administration
|
U.S. Department of Justice Press Release
|
---|
For Immediate Release |
United States Department of Justice District of New Hampshire |
---|
The tampering was discovered when an employee of the pharmacy detected irregularities in certain vials of drugs. After the tampering was discovered, some of the vials were analyzed by an independent laboratory and found to be substantially below their labeled strength.
“Tampering with controlled substances by health care workers is a very serious crime,” said Acting U.S. Attorney Farley. “This type of activity is a betrayal of the trust that patients place in the health care system. Tampering and diversion not only can deprive patients of needed medicine but also can expose patients to other substantial health risks. We will continue to work closely with our law enforcement partners to identify and prosecute health care workers who engage in this very dangerous conduct.”
“Patients deserve to have confidence that they are receiving the proper treatment from those entrusted with providing their medical care,” said Jeffrey J. Ebersole, Special Agent in Charge, FDA Office of Criminal Investigations’ New York Field Office. “We must hold medical personnel accountable when they take advantage of their unique position and tamper with drugs needed by their patients. Tampering can not only endanger the health of patients by exposing them to contaminated products but also may deny them access to the treatments they need.”
“The reckless action by this health care worker is not only a violation of the Controlled Substance Act but a betrayal of the public trust,” said DEA Special Agent in Charge Michael J. Ferguson. “In response to the ongoing opioid epidemic DEA’s obligation is to improve public safety and public health, and we are committed to working with our law enforcement and regulatory partners to ensure that these rules and regulations are followed.”
The investigation was conducted by the United States Food and Drug Administration (FDA) Office of Criminal Investigations and the Drug Enforcement Administration. The case was prosecuted by Assistant United States Attorney Arnold H. Huftalen and Special Assistant United States Attorney Sarah Hawkins of the FDA’s Office of Chief Counsel.
###
Topic(s):
Prescription Drugs
Component(s):
Press Release Number:
18-007